Paolo Ruggeri

Prof. Paolo Ruggeri


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2019 in Journal of Inflammation
Verified
Journal Article
Open access
PDF file
Savino SpadaroSavino Spadaro
Savino Spadaro
MPMirae Park
Mirae Park
CTCecilia Turrini
Cecilia Turrini
TTTanushree Tunstall
Tanushree Tunstall
RTRyan Thwaites
Ryan Thwaites
CVCarlo Alberto Volta
Carlo Alberto Volta
Acute lung injury (ALI) affects over 10% of patients hospitalised in critical care, with acute respiratory distress syndrome (ARDS) being the most severe form of ALI and having a mortality rate in the region of 40%. There has been slow but incremental progress in identification of biomarkers that contribute to the pathophysiology of ARDS, have utility in diagnosis and monitoring, and that are potential therapeutic targets (Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA, Thompson T, Ware LB, Matthay MA, Lancet Respir Med 2014, 2:611–-620). However, a major issue is that ARDS is such a heterogeneous, multi-factorial, end-stage condition that the strategies for “lumping and splitting” are critical (Prescott HC, Calfee CS, Thompson BT, Angus DC, Liu VX, Am J Respir Crit Care Med 2016, 194:147–-155). Nevertheless, sequencing of the human genome, the availability of improved methods for analysis of transcription to mRNA (gene expression), and development of sensitive immunoassays has allowed the application of network biology to ARDS, with these biomarkers offering potential for personalised or precision medicine (Sweeney TE, Khatri P, Toward precision medicine Crit Care Med; 2017 45:934-939). Biomarker panels have potential applications in molecular phenotyping for identifying patients at risk of developing ARDS, diagnosis of ARDS, risk stratification and monitoring. Two subphenotypes of ARDS have been identified on the basis of blood biomarkers: hypo-inflammatory and hyper-inflammatory. The hyper-inflammatory subphenotype is associated with shock, metabolic acidosis and worst clinical outcomes. Biomarkers of particular interest have included interleukins (IL-6 and IL-8), interferon gamma (IFN-γ), surfactant proteins (SPD and SPB), von Willebrand factor antigen, angiopoietin 1/2 and plasminogen activator inhibitor-1 (PAI-1). In terms of gene expression (mRNA) in blood there have been found to be increases in neutrophil-related genes in sepsis-induced and influenza-induced ARDS, but whole blood expression does not give a robust diagnostic test for ARDS. Despite improvements in management of ARDS on the critical care unit, this complex disease continues to be a major life-threatening event. Clinical trials of β2-agonists, statins, surfactants and keratinocyte growth factor (KGF) have been disappointing. In addition, monoclonal antibodies (anti-TNF) and TNFR fusion protein have also been unconvincing. However, there have been major advances in methods of mechanical ventilation, a neuromuscular blocker (cisatracurium besilate) has shown some benefit, and stem cell therapy is being developed. In the future, by understanding the role of biomarkers in the pathophysiology of ARDS and lung injury, it is hoped that this will provide rational therapeutic targets and ultimately improve clinical care (Seymour CW, Gomez H, Chang CH, Clermont G, Kellum JA, Kennedy J, Yende S, Angus DC, Crit Care 2017, 21:257).

1 November 2010 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
GPGiovanni Battista Pajno
Giovanni Battista Pajno
LCLucia Caminiti
Lucia Caminiti
Paolo RuggeriPaolo Ruggeri
Paolo Ruggeri
RLRaffaele De Luca
Raffaele De Luca
DVDaniela Vita
Daniela Vita
GPGiovanni Passalacqua
Giovanni Passalacqua

1 July 2015 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
LCLucia Caminiti
Lucia Caminiti
GPGiovanni B. Pajno
Giovanni B. Pajno
GCGiuseppe Crisafulli
Giuseppe Crisafulli
FCFernanda Chiera
Fernanda Chiera
MCMirella Collura
Mirella Collura
GPGiovanni Passalacqua
Giovanni Passalacqua

1 October 2007 in Pulmonary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
MCMario Cazzola
Mario Cazzola
FAFilippo Andò
Filippo Andò
PSPierachille Santus
Pierachille Santus
Paolo RuggeriPaolo Ruggeri
Paolo Ruggeri
Fabiano Di MarcoFabiano Di Marco
Fabiano Di Marco
GDGennaro D'Amato
Gennaro D'Amato

1 April 2010 in Allergy
Verified
Journal Article
Closed access
PDF file
DVD. Vita
D. Vita
LCL. Caminiti
L. Caminiti
Paolo RuggeriPaolo Ruggeri
Paolo Ruggeri
GPGiovanni Battista Pajno
Giovanni Battista Pajno

11 May 2019 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
Gaetano CaramoriGaetano Caramori
Gaetano Caramori
Paolo RuggeriPaolo Ruggeri
Paolo Ruggeri
SMSharon Mumby
Sharon Mumby
AIAntonio Ieni
Antonio Ieni
FBFederica Lo Bello
Federica Lo Bello
IAIan Adcock
Ian Adcock
Introduction: COPD and lung cancer are leading causes of morbidity and mortality worldwide, and they share a common environmental risk factor in cigarette smoke exposure and a genetic predisposition represented by their incidence in only a fraction of smokers. This reflects the ability of cigarette smoke to induce an inflammatory response in the airways of susceptible smokers. Moreover, COPD could be a driving factor in lung cancer, by increasing oxidative stress and the resulting DNA damage and repression of the DNA repair mechanisms, chronic exposure to pro-inflammatory cytokines, repression of innate immunity and increased cellular proliferation. Areas covered: We have focused our review on the potential pathogenic molecular links between tobacco smoking-related COPD and lung cancer and the potential molecular targets for new drug development by understanding the common signaling pathways involved in COPD and lung cancer. Expert commentary: Research in this field is mostly limited to animal models or small clinical trials. Large clinical trials are needed but mostly combined models of COPD and lung cancer are necessary to investigate the processes caused by chronic inflammation, including genetic and epigenetic alteration, and the expression of inflammatory mediators that link COPD and lung cancer, to identify new molecular therapeutic targets.